Clinical Trial Update: Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study of lenalidomide in relapsed and/or refractory peripheral T-cell lymphomas was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Peripheral T-cell Lymphomas, Adult T-cell Leukemia | EARLY_Phase 1 | Status: TERMINATED